Novel therapeutic approaches in the treatment of irritable bowel syndrome

2007 ◽  
Vol 148 (20) ◽  
pp. 923-928 ◽  
Author(s):  
István Pregun ◽  
László Herszényi ◽  
Márk Juhász ◽  
Pál Miheller ◽  
Zsolt Tulassay
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Approaches ◽  
Irritable Bowel ◽  
Novel Therapeutic

Az irritábilis bél szindróma (IBS) kezelése a változatos tünetek, a társuló neuropszichiátriai kórképek miatt nem könnyű feladat. Bár számos, különböző támadáspontú szert alkalmazunk a betegség kezelésére, a mai napig kevés olyan gyógyszer van, amelynek hatékonyságáról, biztonságosságáról és tolerabilitásáról egyértelmű bizonyítékok állnak rendelkezésre. Az IBS multikauzális jellegéből adódóan a visceralis hiperszenzitivitással, a motilitással, az agy-bél tengely szabályozási zavaraival kapcsolatos kutatások eredményei, a folyamatokban központi szerepet játszó neurotranszmitterek, ezek receptorainak megismerése teremtette meg az új kezelési lehetőségek alapját. Bár napjainkban néhány gyógyszert (alosetron, tegaserod) már törzskönyveztek egyes országokban IBS-ben, az új készítményekkel kapcsolatban még több, nagy betegszámú vizsgálatra van szükség.

Su1988 Novel Therapeutic Approaches for Treatment of Irritable Bowel Syndrome Using the Multi-Herbal Drug STW 5

2012 ◽  
Vol 142 (5) ◽  
pp. S-554
Author(s):  
Karen Nieber ◽  
Ulrike Voss ◽  
Stefanie Hoser ◽  
Sebastian Michael ◽  
Heba Abdel-Aziz ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Herbal Drug ◽  
Therapeutic Approaches ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals A sustained hypothalamic–pituitary–adrenal axis response to acute psychosocial stress in irritable bowel syndrome

2014 ◽  
Vol 44 (14) ◽  
pp. 3123-3134 ◽  
Author(s):  
P. J. Kennedy ◽  
J. F. Cryan ◽  
E. M. M. Quigley ◽  
T. G. Dinan ◽  
G. Clarke
Keyword(s):  
Irritable Bowel Syndrome ◽  
Hpa Axis ◽  
Psychosocial Stress ◽  
Trier Social Stress Test ◽  
Hypothalamic Pituitary Adrenal ◽  
Gi Symptoms ◽  
Irritable Bowel ◽  
Acute Psychosocial Stress ◽  
Novel Therapeutic ◽  
The Way

BackgroundDespite stress being considered a key factor in the pathophysiology of the functional gastrointestinal (GI) disorder irritable bowel syndrome (IBS), there is a paucity of information regarding the ability of IBS patients to respond to acute experimental stress. Insights into the stress response in IBS could open the way to novel therapeutic interventions. To this end, we assessed the response of a range of physiological and psychological parameters to the Trier Social Stress Test (TSST) in IBS.MethodThirteen female patients with IBS and 15 healthy female age-matched control participants underwent a single exposure to the TSST. Salivary cortisol, salivary C-reactive protein (CRP), skin conductance level (SCL), GI symptoms, mood and self-reported stress were measured pre- and post-exposure to the TSST.ResultsThe hypothalamic–pituitary–adrenal (HPA) axis response to the TSST was sustained in IBS, as shown by a greater total cortisol output throughout (p = 0.035) and higher cortisol levels measured by an area under the curve with respect to ground (AUCG) analysis (p = 0.044). In IBS patients, GI symptoms increased significantly during the recovery period following exposure to the TSST (p = 0.045). Salivary CRP and SCL activity showed significant changes in relation to stress but with no differential effect between experimental groups.ConclusionsPatients with IBS exhibit sustained HPA axis activity, and an increase in problematic GI symptoms in response to acute experimental psychosocial stress. These data pave the way for future interventional studies aimed at identifying novel therapeutic approaches to modulate the HPA axis and GI symptom response to acute psychosocial stress in IBS.

scholarly journals Agomelatine, a novel therapeutic option for the management of irritable bowel syndrome

2018 ◽  
Vol 43 (5) ◽  
pp. 752-756 ◽  
Author(s):  
Qin Xiang Ng ◽  
Alex Yu Sen Soh ◽  
Donovan Yutong Lim ◽  
Wee‐Song Yeo
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Option ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals Evaluation of the Pharmacological Profile of Ramosetron, a Novel Therapeutic Agent for Irritable Bowel Syndrome

2007 ◽  
Vol 104 (3) ◽  
pp. 263-273 ◽  
Author(s):  
Takuya Hirata ◽  
Yoshihiro Keto ◽  
Toshiyuki Funatsu ◽  
Shinobu Akuzawa ◽  
Masao Sasamata
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Agent ◽  
Pharmacological Profile ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals Pharmacological and clinical profile of ramosetron hydrochloride (Irribow®), a novel therapeutic agent for irritable bowel syndrome with diarrhea

2009 ◽  
Vol 133 (5) ◽  
pp. 281-291
Author(s):  
Takuya Hirata ◽  
Toshiyuki Funatsu ◽  
Yoshihiro Keto ◽  
Shinobu Akuzawa ◽  
Hiraku Akiho ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Agent ◽  
Clinical Profile ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

2020 ◽  
Vol 9 (3) ◽  
pp. 685 ◽  
Author(s):  
Amir Mari ◽  
Fadi Abu Baker ◽  
Mahmud Mahamid ◽  
Wisam Sbeit ◽  
Tawfik Khoury
Keyword(s):  
Irritable Bowel Syndrome ◽  
Current Knowledge ◽  
Gastrointestinal Disorder ◽  
Economic Effects ◽  
Therapeutic Approaches ◽  
High Prevalence ◽  
Attractive Option ◽  
Irritable Bowel ◽  
Substantial Morbidity

The intestinal microbiota is one of the most rapidly evolving areas in biology and medicine. Extensive research in the last decade has escalated our understanding of the role of the microbiota in the pathogenesis of several intestinal and extra-intestinal disorders. Marked by high prevalence, substantial morbidity, and enormous costs, irritable bowel syndrome (IBS) is an important chronic gastrointestinal disorder that is widely encountered by gastroenterologists. Despite advances in our understanding of its pathophysiology, curative interventions have yet to be discovered, and therapeutic approaches remain symptom-driven. Recently, accumulating evidence has enlightened the possible impact of an imbalanced gut microbiome in the pathogenesis of IBS. In fact, several studies have documented altered microbiota in patients, while others have shown that IBS severity was associated with a distinct microbiota signature. These findings may pave the way for the use of microbiota manipulation strategies as an attractive option for IBS management, and may have an essential role in efforts to reduce the societal and economic effects of this ever-growing disorder. In this review, we have outlined the results of the latest research on the association between microbiota and IBS and their implications for the clinical management of affected patients.

Sign in / Sign up

Export Citation Format

Share Document